First preclinical SPECT/CT imaging and biodistribution of [Er]ErCl and [Er]Er-PSMA-617.

Background: Er (t = 10.4 h, E = 47.1 keV (59.

Development of thiacrown ligands for encapsulation of mercury-197m/g into radiopharmaceuticals.

The theranostic pair mercury-197m and mercury-197g (Hg, = 23.8 h/64.14 h), through their γ rays and Meitner-Auger electron emissions, have potential use as constituents in radiopharmaceuticals to treat small metastatic tumours.

Preclinical Evaluation of Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Ac (t = 29.37 h) has been proposed as a theranostic radioisotope leveraging both its diagnostic γ-emissions and therapeutic α-emissions. Ac emits 158 and 230 keV γ-photons ideal for quantitative SPECT imaging and acts as an in vivo generator of 4 high-energy α-particles.

Quantitative SPECT imaging of Tb and Tb for preclinical theranostic radiopharmaceutical development.

Background: Element-equivalent matched theranostic pairs facilitate quantitative in vivo imaging to establish pharmacokinetics and dosimetry estimates in the development of preclinical radiopharmaceuticals. Terbium radionuclides have significant potential as matched theranostic pairs for multipurpose applications in nuclear medicine. In particular, Tb (t = 5.

Chemistry of Antimony in Radiopharmaceutical Development: Unlocking the Theranostic Potential of Sb Isotopes.

Antimony-119 (Sb) holds promise for radiopharmaceutical therapy (RPT), emitting short-range Auger and conversion electrons that can deliver cytotoxic radiation on a cellular level. While it has high promise theoretically, experimental validation is necessary for Sb in vivo applications. Current Sb production and separation methods face robustness and compatibility challenges in radiopharmaceutical synthesis.